The object of this study was to clarify the expression characteristics and prognostic value of survivin in skull base chordomas.
In this retrospective study, the authors measured the expression of survivin at the mRNA level in 81 samples from 71 patients diagnosed with skull base chordomas at their hospital in the period from July 2005 to January 2015. Clinical data collection, follow-up, and survival analyses were performed, and correlations were analyzed.
Of the 71 patients, 50 had primary chordomas with a mean survivin expression level of 1.09; the other 21 patients had recurrent chordomas with a mean survivin expression level of 2.57, which was 2.36 times higher than the level in the primary chordoma patients (p < 0.001, Mann-Whitney U-test). In addition, an analysis of 18 paired samples derived from 9 patients showed that the expression level of survivin was 2.62 times higher in recurrent tumors than in primary tumors (p = 0.002, paired t-test). The Spearman rank correlation coefficient method showed that the expression level of survivin was positively correlated with the mean ratio of tumor signal intensity to the signal intensity of surrounding brainstem on T1-weighted sequences (RT1; rs = 0.274, p = 0.021) and was negatively correlated with the mean ratio of tumor signal intensity to the signal intensity of surrounding brainstem on T2-weighted sequences (RT2; rs = −0.389, p = 0.001). A multivariate Cox proportional-hazards model suggested that pathology (p = 0.041), survivin expression level (p = 0.018), preoperative Karnofsky Performance Status (KPS; p = 0.012), and treatment history (p = 0.009) were independent prognostic factors for tumor progression. Survivin expression level (p = 0.008), preoperative KPS (p = 0.019), tumor diameter (p = 0.027), and intraoperative blood loss (p = 0.015) were independent prognostic factors for death.
Survivin expression level and preoperative KPS were independent significant prognostic factors for tumor progression and death in skull base chordoma patients. Recurrent skull base chordomas and chordomas with high RT1 and low RT2 were likely to have high survivin expression. Other independent risk factors related to tumor progression included conventional pathology and treatment history, whereas additional mortality-related risk factors included larger tumor diameter and greater intraoperative blood loss.
ABBREVIATIONSELS = expression level of survivin; GTR = gross-total resection; KPS = Karnofsky Performance Status; OS = overall survival; PFS = progression-free survival; PR = partial resection; RCE = ratio of mean signal intensity of tumor to mean signal intensity of surrounding brainstem on contrast-enhanced MRI sequence; RT1 = ratio of mean signal intensity of tumor to mean signal intensity of surrounding brainstem on T1-weighted MRI sequence; RT2 = ratio of mean signal intensity of tumor to mean signal intensity of surrounding brainstem on T2-weighted MRI sequence; SBC = skull base chordoma; STR = subtotal resection.
EversPDLoganJESillsVChinAI: Karnofsky performance status predicts overall survival, cancer-specific survival, and progression-free survival following radical cystectomy for urothelial carcinoma. World J Urol32:385–3912014
IngrischMSchneiderMJNörenbergDNegrao de FigueiredoGMaier-HeinKSuchorskaB: Radiomic analysis reveals prognostic information in T1-weighted baseline magnetic resonance imaging in patients with glioblastoma. Invest Radiol52:360–3662017
MiuraTHiranoSNakamuraTTanakaEShichinoheTTsuchikawaT: A new preoperative prognostic scoring system to predict prognosis in patients with locally advanced pancreatic body cancer who undergo distal pancreatectomy with en bloc celiac axis resection: a retrospective cohort study. Surgery155:457–4672014
OtaniRMukasaAShinMOmataMTakayanagiSTanakaS: Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic brachyury expression in skull base chordoma. J Neurosurg128:1428–14372018
PreusserMWolfsbergerSCzechTSlavcIBudkaHHainfellnerJA: Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol124:543–5492005
SaitoTSugiyamaKTakeshimaYAmatyaVJYamasakiFTakayasuT: Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurosurg128:679–6842018
SchuetzeSMBolejackVChoyEGanjooKNStaddonAPChowWA: Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer123:90–972017
ShengLWanBFengPSunJRigoFBennettCF: Downregulation of Survivin contributes to cell-cycle arrest during postnatal cardiac development in a severe spinal muscular atrophy mouse model. Hum Mol Genet27:486–4982018
UhlMMattkeMWelzelTRoederFOelmannJHablG: Highly effective treatment of skull base chordoma with carbon ion irradiation using a raster scan technique in 155 patients: first long-term results. Cancer120:3410–34172014